SI-BONE, Inc. (SIBN): Price and Financial Metrics
GET POWR RATINGS... FREE!
SIBN POWR Grades
- SIBN scores best on the Growth dimension, with a Growth rank ahead of 59.67% of US stocks.
- The strongest trend for SIBN is in Stability, which has been heading down over the past 179 days.
- SIBN's current lowest rank is in the Sentiment metric (where it is better than 21.8% of US stocks).
SIBN Stock Summary
- SIBN's went public 4.3 years ago, making it older than only 20.51% of listed US stocks we're tracking.
- The ratio of debt to operating expenses for SI-BONE INC is higher than it is for about just 24.54% of US stocks.
- SIBN's price/sales ratio is 5.89; that's higher than the P/S ratio of 79.92% of US stocks.
- If you're looking for stocks that are quantitatively similar to SI-BONE INC, a group of peers worth examining would be SVFD, APYX, XXII, BLDE, and IRTC.
- Visit SIBN's SEC page to see the company's official filings. To visit the company's web site, go to si-bone.com.
SIBN Valuation Summary
- In comparison to the median Healthcare stock, SIBN's price/sales ratio is 13.73% higher, now standing at 5.8.
- Over the past 52 months, SIBN's price/earnings ratio has gone up 15.5.
Below are key valuation metrics over time for SIBN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SIBN | 2023-01-30 | 5.8 | 5.6 | -8.9 | -9.5 |
SIBN | 2023-01-27 | 6.0 | 5.8 | -9.2 | -9.8 |
SIBN | 2023-01-26 | 6.0 | 5.8 | -9.2 | -9.8 |
SIBN | 2023-01-25 | 5.9 | 5.7 | -9.1 | -9.7 |
SIBN | 2023-01-24 | 6.1 | 5.9 | -9.3 | -9.9 |
SIBN | 2023-01-23 | 6.1 | 5.9 | -9.4 | -9.9 |
SIBN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SIBN has a Quality Grade of C, ranking ahead of 32.78% of graded US stocks.
- SIBN's asset turnover comes in at 0.425 -- ranking 111th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows SIBN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.425 | 0.889 | -0.227 |
2021-03-31 | 0.409 | 0.881 | -0.230 |
2020-12-31 | 0.417 | 0.879 | -0.268 |
2020-09-30 | 0.475 | 0.878 | -0.305 |
2020-06-30 | 0.473 | 0.884 | -0.313 |
2020-03-31 | 0.519 | 0.896 | -0.281 |
SIBN Price Target
For more insight on analysts targets of SIBN, see our SIBN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $40.86 | Average Broker Recommendation | 1.36 (Strong Buy) |
SIBN Stock Price Chart Interactive Chart >
SIBN Price/Volume Stats
Current price | $18.09 | 52-week high | $23.71 |
Prev. close | $17.05 | 52-week low | $11.14 |
Day low | $16.69 | Volume | 227,599 |
Day high | $18.11 | Avg. volume | 222,455 |
50-day MA | $13.90 | Dividend yield | N/A |
200-day MA | $15.45 | Market Cap | 624.03M |
SI-BONE, Inc. (SIBN) Company Bio
SI-BONE, Inc. engages in the development of invasive surgical implant system. Its product, iFuse, seeks to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded on April 2008 by Mark A. Reiley and Jeffrey W. Dunn in and is headquartered in San Jose, CA.
Latest SIBN News From Around the Web
Below are the latest news stories about SI-BONE INC that investors may wish to consider to help them evaluate SIBN as an investment opportunity.
SI-BONE Inc. (NASDAQ: SIBN) Stock Jumped 44.50% Over A Month – Is There Any Hope Of A Gain?During the last session, SI-BONE Inc. (NASDAQ:SIBN)’s traded shares were 0.33 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stock’s price was $17.21, reflecting an intraday gain of 6.23% or $1.01. The 52-week high for the SIBN share is $23.71, that puts it down -37.77 … SI-BONE Inc. (NASDAQ: SIBN) Stock Jumped 44.50% Over A Month – Is There Any Hope Of A Gain? Read More » |
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2022Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26% Fiscal Year 2022 revenue of $106.1 - $106.3 million representing growth of approximately 18% |
SI-BONE guides Q4 and FY22 revenue above estimatesSI-Bone (SIBN) expects Q4 worldwide revenue to be in the range of $31.7M-$31.9M, representing growth of ~26% Y/Y, vs consensus of $30.05M.Q4 U.S. revenue expected to be in the range… |
SI-BONE to Host a Virtual Fireside Chat at the 25th Annual Needham Growth ConferenceSANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 25th Annual Needham Growth Conference. Management will be hosting a virtual fireside chat on Thursday, January 12th, 2023, at 11:45 a.m. Eastern Time / 8:45 a.m. Pacific Time. A live webcast of each event, as well as an archived recording will |
SI-BONE Stock: Multiple Inflection Points On The Horizon In FY 2023 (NASDAQ:SIBN)SI-BONE presents as an operator in the surgical intervention of sacroiliac disorders. There are inflection points on the horizon. See why we believe SIBN is a buy. |
SIBN Price Returns
1-mo | 35.81% |
3-mo | 9.57% |
6-mo | 8.39% |
1-year | -5.49% |
3-year | -13.98% |
5-year | N/A |
YTD | 33.01% |
2022 | -38.77% |
2021 | -25.72% |
2020 | 39.07% |
2019 | 2.92% |
2018 | N/A |
Continue Researching SIBN
Here are a few links from around the web to help you further your research on SI-BONE Inc's stock as an investment opportunity:SI-BONE Inc (SIBN) Stock Price | Nasdaq
SI-BONE Inc (SIBN) Stock Quote, History and News - Yahoo Finance
SI-BONE Inc (SIBN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...